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Abstract 
Objectives: To evaluate co-infection of Strongyloides stercoralis and Trypanosoma cruzi and to assess 
eosinophilia as a screening test for detection of S. stercoralis infection in patients with Chagas disease 
(CD).
Methods: A retrospective diagnostic validation study was performed on serum samples from primary care 
patients diagnosed with CD in the southern Barcelona metropolitan area. All samples with eosinophilia  
(n=87) and a random sample of non-eosinophilic sera (n=180) were selected. Diagnosis of CD was based 
on positive serology by means of two tests: ORTHO® T. cruzi ELISA test, and BIO-FLASH® Chagas or Bioelisa 
CHAGAS. SCIMEDX ELISA STRONGY-96 was used to diagnose strongyloidiasis.
Results: S. stercoralis serology was positive in 15% of patients of whom 95% showed eosinophilia, vs. 21% 
of those with negative serology (p<0.001), with differences in the mean eosinophil count (0.49 vs. 0.27 x 
109/L). Only 1.1% of patients with CD but without eosinophilia presented positive serology for S. 
stercoralis; whereas 44% of patients with CD and eosinophilia did (p<0.001). Sensitivity and specificity 
values for eosinophilia were thus 95% and 79% respectively. PPV was 42.5% and NPV, 98.9%.
Conclusions: The prevalence of co-infection by T. cruzi and S. stercoralis is not negligible and has probably 
been underestimated for years in many areas, due to frequently subclinical infections. Therefore, serology 
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task, decreasing the number of analyses to be performed.
Keywords: Chagas disease, T. cruzi, S. stercoralis, eosinophilia, co-infection, retrospective diagnostic 
validation, Spain
Introduction
The neglected tropical diseases (NTDs) are a group of parasitic, viral, fungal and bacterial infections that 
also include snakebites. So far NTDs had received miniscule treatment and research funding compared to 
better-known infections  such as HIV/AIDS, tuberculosis and malaria. According to WHO, NTDs affect 
more than one billion of the world’s poorest people each year, causing an estimated 534 000 deaths, 
mainly in socioeconomically disadvantaged areas with tropical and subtropical climates. [1] One of these 
conditions is Chagas disease (CD): a protozoan infection produced by Trypanosoma cruzi, which in 80% of 
cases is transmitted by triatomine insects, with other transmission routes being oral, blood-borne, 
vertical, via organ transplantation and as a result of laboratory accidents. The disease is endemic in 21 
countries of Latin America with the greatest presence in the Southern Cone. [2] Its prevalence is 
estimated to be between 6 and 7 million people, most of whom are unaware of their infection. [3] Chagas 
disease presents an acute phase and an indeterminate asymptomatic chronic phase which in 30%-40% of 
cases evolves to the symptomatic phase, mainly affecting cardiac or digestive function. [4]
Strongyloidiasis is a soil-transmitted helminthiasis produced by the intestinal nematode Strongyloides 
stercoralis, which will soon be included in the NTD group. Its transmission occurs in tropical and 
subtropical regions and occasionally in temperate climates (the south of Europe) when skin comes into 
contact with contaminated wet soils. According to WHO, between 30 and 100 million people are infected 
around the world. [5] Although there are few studies on the prevalence of this infection in Latin America, 
estimations suggest that it is higher than 20% in Argentina, Bolivia, Brazil, Ecuador, Peru and Venezuela. 
[6, 7] In Spain, several autochthonous cases have been reported, [8] but the vast majority are imported 
and their incidence is increasing. [9,10] Chronic infections by S. stercoralis can produce skin, 
gastrointestinal and cardiopulmonary manifestations, and when coinciding with immunosuppressive 
conditions, hyperinfestation syndrome can occur, which is lethal in up to 85% of cases. [11]
CD and strongyloidiasis appear in non-endemic countries due to migratory flows. The parasites 
causing both conditions can persist in the host for decades, even throughout the whole of life, often 
resulting in asymptomatic disease. [12-14] Recently, in Spain, studies have been published linking CD and 
infection by S. stercoralis. (15)
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basic test that is routinely performed. A result showing unexplained eosinophilia could constitute a 
valuable screening tool for the detection of S. stercoralis, as it appears in 75% of cases. [16] In a British 
Infection Society clinical guide, it is recommended that all travellers returning from tropical areas with 
eosinophilia should be tested by means of concentrated microscopy of faeces and Strongyloides serology, 
among other techniques. However, the same guide warns that the first method presents low sensitivity, 
while serology may present problems of cross-reaction with soil-transmitted helminths. [17] The low 
sensitivity of standard stool examination is related to the fact that larvae are excreted intermittently, 
especially in patients with a low burden of infection. Serological diagnosis by enzymatic-immune assay 
(EIA) presents sensitivity of around 85%, depending on the different tests, and a specificity >95%, 
demonstrating a high negative predictive value. [11,18,19]
In Spain, in general terms, 70% of the population visit their primary care centre at least once a year, 
[20] so this offers an excellent framework within which to screen, diagnose, treat and follow-up 
immigrant patients, due to its accessibility and the continuity of care. Therefore, the main objective of the 
present work was to conduct a study in our area, where primary care serves a high proportion of 
immigrant patients, to evaluate co-infection of S. stercoralis and T. cruzi and furthermore to assess 
eosinophilia as a screening test for S. stercoralis infection in CD patients.
Material and Methods
Design 
We performed a retrospective diagnostic validation study. In the design and presentation of the results of 
the study, we have followed the recommendations for reporting studies on diagnostic accuracy: 
Standards for Reporting Diagnostic Accuracy (STARD). [21]
Subjects
This study was carried out on patients who attended primary care centres between 2011 and 2018 in the 
southern area of metropolitan Barcelona with a population of app. 1.2 million, of whom some 5% are 
Latin American migrants.
Eligibility of the sample and source population
Surplus anonymous samples of serum from patients diagnosed with CD were analysed. The collection of 
sera is registered and authorized by the Instituto de Salud Carlos III with access number CO0041 9. All 
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Of the total number of sera from patients with CD (n= 887) with available eosinophil count 
information (n=766), all samples with eosinophilia were selected (n=87), plus a random sample of non-
eosinophilic sera (n=180) (Figure 1). This sample was calculated taking into account an estimated 
proportion of 14% of patients with CD being co-infected with Strongyloides, with an accuracy of +/- 5% 
and a confidence level of 95%. [ 15,22] All selected sera were tested for S. stercoralis IgG, taking it as a 
reference test for the diagnosis of Strongyloides infection and then using it as the benchmark for 
comparison with the results of the eosinophil count.
All samples were collected, stored and processed according to standard recommendations for 
serology. Each sample received an identification code in the laboratory, which corresponded to an 
encrypted identifier to guarantee blind analysis without the possibility of identification of any patient.
Processing of laboratory samples
Diagnosis of CD was based on positive serology by means of two tests: the ORTHO® T. cruzi ELISA test 
(Ortho Clinical Diagnostics Inc., Raritan, USA) based on the T. cruzi whole-cell lysate antigen, and either 
BIO-FLASH® Chagas (automated chemiluminescent immunoassay; Biokit S.A., Barcelona, Spain) or Bioelisa 
CHAGAS (Biokit S.A., Barcelona, Spain), which employ recombinant T. cruzi proteins as antigens. Samples 
that returned discordant results (after three tests: one with native antigen and two with recombinant 
ones) or those judged inconclusive were excluded.
The eosinophil count was performed in an ABX Pentra DX120® autoanalyzer (Horiba Medical, Kyoto, 
Japan); eosinophilia was classified as mild (> 0.50-1.5 x 109 eos/L), moderate (1.5-3.0 x 109 eos/L) or high 
(> 3 x 109 eos/L). [23] 
To diagnose strongyloidiasis, we used SCIMEDX ELISA (STRONGY-96, SciMedx Corporation, Denville, 
NJ, USA), which employs a soluble fraction of S. stercoralis filariform larvae as an antigen. Briefly, serum 
was diluted to 1:64 in dilution buffer, and 100 µl was pipetted into microtitre wells coated with 
Strongyloides antigen and incubated at 15ºC to 25ºC for 10 min. The wells were washed three times, and 
100 µl of the supplied horseradish peroxidase-conjugated protein A was added and incubated for 5 min at 
15ºC to 25ºC. The wells were washed three times and 100 µl of chromogen tetramethylbenzidine (TMB) 
was added and incubated for 5 min at 15ºC to 25ºC, followed by the addition of 100 µl of stop solution 
(0.73 M phosphoric acid). The optical density (OD) was subsequently measured at a wavelength of 450 nm 
(BEST 2000®, Biokit, Werfen Group Barcelona, Spain) and divided by the cut-off indicated by the 
manufacturer (0.2) to give an index value (IV): IV >1.1 was considered positive; from 0.9 to 1.1, 
indeterminate; and <0.9, negative. 
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test for T. cruzi, gender and country of origin.
Statistical analysis
First, univariate descriptive analysis was carried out by frequency distribution and percentages for the 
qualitative variables (gender, age group, country of origin, eosinophilia (YES/NO), degree of eosinophilia, 
positive S. stercoralis serology (YES/NO)). Data analysis was conducted using the IBM SPSS Version 25.0. 
(IBM Corp, Armonk, NY, USA).
For the quantitative variables (age, eosinophil count, and reactivity index for S. stercoralis), the 
analysis consisted of calculating the mean, median, standard deviation (SD) and percentiles. 
Subsequently, bivariate analysis was performed, relating the presence or absence of IgG anti-S. stercoralis 
and eosinophilia with the other variables in the study. Finally, the association between S. stercoralis 
infection and eosinophilia in T. cruzi-positive individuals was studied by calculating the odds ratio (OR) 
using cross-product ratios of 2 x 2 tables with 95% confidence intervals (CI). p-values of 0.05 or less were 
used in the 2-sided tests as criteria for statistically significant differences. The SP, S, and positive and 
negative predictive values (PPV and NPV) with 95% CI were calculated by comparing the results of the 
eosinophil count with the S. stercoralis serology as the reference test. For the comparison, indeterminate 
values were excluded.
Ethics
This study was reviewed and approved by the Institutional Review Board (IRB) at IDIBELL (PR57/19), 
Barcelona, Spain. All patient data were anonymized for this analysis. The implementation of the research 
project did not alter usual patient care. Patient information was protected according to the General Data 
Protection Regulation (2016/679) of the Council of the European Union, which came into force on 
25/05/2018 on the protection of natural persons with regard to the processing of personal data; and 
Spanish Organic Law 15/1999. 
Results
Of the 267 patients with CD, 73% were women. All cases except four were adults (18 or more years old) 
with an average age of 37.2 years (SD 10.5). Of the 197 patients whose country of origin was known, 95% 
were Bolivian. Of the 87 patients with eosinophilia, 77 (89%) presented mild eosinophilia and 10 (11%) 
with moderate, with no cases of high eosinophilia. The mean eosinophil count was 0.4157 eosinophils x 
109/L (SD 0.41698) (Table 1).
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were excluded (3 with eosinophilia and 1 without). Regarding the data of patients in whom S. stercoralis 
serology was performed, the proportion of men was higher in positive cases (16, 40%) than in negative 
ones (54, 24%) (p=0.038). Patients with antibodies to S. stercoralis showed eosinophilia in 38 cases (95%), 
vs. 46 (21%) patients without (p<0.001), also showing statistically significant differences in the mean 
eosinophil counts (Table 1).
It should be noted that of the 179 patients with CD but without eosinophilia, only 2 (1%) presented 
positive serology for S. stercoralis whereas 38 (45%) of the 84 patients with CD and eosinophilia did 
(p<0.001) (Table 1). 
Table 2 shows the simple and age-sex-adjusted ratios of the association between eosinophilia and the 
presence of antibodies against S. stercoralis. Eosinophilia maintains a significant association with positive 
serology, whereas sex is not significant.
Table 3 shows the data of the eosinophil count parameter as a diagnostic screening test. The 
sensitivity and specificity of eosinophilia were 95% (CI 95%, 82%–99%) and 79% (CI 95%, 73%–84%) 
respectively. The PPV was 42% (CI 95%, 34%–56%), the NPV was 98.9% (CI 95%, 95.6%–99.8%).
Discussion 
We present a study of 267 serum samples from patients with CD who attended primary care centres of 
the southern Barcelona metropolitan area during the period 2011 to 2018. Of these patients, 15% also 
presented strongyloidiasis, proportionately more men and more patients with eosinophilia; although in 
the adjusted analysis, only the relevance of eosinophilia was confirmed. Eosinophilia showed a sensitivity 
of 95% for diagnosis of S. stercoralis infection in patients with CD. 
There is considerable prevalence of T. cruzi infection among the Latin-American migrant population 
who attend primary care centres in our area: 3.6% overall but up to 13.7% among Bolivian migrants 
specifically. [24] Studies have recently been published in Spain, showing that T. cruzi and S. stercoralis co-
infection occurs in 16.7% of chronic CD patients. [22] In the present work, we obtained a positive result in 
40 cases (15%) of CD patients: in line with the results obtained by others. [15,22] The observed 
differences regarding sex (greater proportion in men) probably correspond to activities of men (such as 
agriculture without footwear), which correlate with the chance of contact with S. stercoralis. [25]
Data concerning the prevalence of S. stercoralis in Spain, relating to native and migrant populations, 
are diverse. In one study of a native population infected with S. stercoralis in eastern Spain, a prevalence 
of 12.4% was found, with 83.7% of the patients presenting eosinophilia. This laboratory parameter was 
considered the best infection prognostic factor. [26] In another study of 70 cases of strongyloidiasis based 
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cases. [14] In a review of intestinal parasitism of patients from the southern Barcelona metropolitan area 
(2001 to 2010), in which 78 cases of S. stercoralis infection were studied, 90% had eosinophilia. [27] 
Moreover, in a recent systematic review of endemic strongyloidiasis in Spain, eosinophilia was 
documented in 82% of cases. [28] However, in a case–control study of a sample of patients treated at a 
tropical diseases unit in Barcelona, the authors found that only 38.5% of patients with S. stercoralis 
infection had absolute eosinophilia and that patients with CD were more than twice as likely to be 
infected by T. cruzi. [29] In our study, almost half of the patients with CD and eosinophilia (45%) were 
infected with Strongyloides. Moreover, 95% of patients with S. stercoralis showed eosinophilia: a slightly 
higher prevalence than that found in previous studies, probably due to the selection of the sample for our 
study (only patients with CD). It is unknown whether an association between the 2 parasites exists, 
although it seems likely, given their close relationship when both geographical and socioeconomic risk 
factors are shared. Bearing in mind the regulation of host immune system by S. stercoralis, [30] in case of 
co-infection it could affect the response to the protozoan and affect the evolution of CD via an underlying 
modulation of cytokine responses. In a study of blood donors, it was found that 10.9% of patients with CD 
were co-infected with S. stercoralis, presenting a greater proportion of PCR-positivity for T. cruzi than 
patients with negative Strongyloides serology. [15]
Eosinophilia presents a high NPV (99%), corresponding quite well with the values obtained by other 
authors working in the area. [14,26,27] This is a high value when referring to the aim of establishing this 
determination as a screening test, bearing in mind that the eosinophil count is included in any 
haemogram. In Latin American patients with eosinophilia in whom T. cruzi infection is not detected, the 
prevalence of S. stercoralis infection is 28%. [31]
The strengths of the present study include the fact that in our type of population, the absence of 
eosinophilia would allow a large number of sera not to be tested for S. stercoralis antibodies. This could 
improve cost-effectiveness at a time when active screening for S. stercoralis is increasingly advocated. 
[32] 
Regarding to the cut-off used in Strongyloides serology, in our experience it is specific enough with no 
cross-reactions with other intestinal parasitic infections except hookworms. [32] The possibility of 
unnoticed cross-reactions with hookworms due to the lack of a copro-parasitological study, and the fact 
that the percentage of eosinophilic patients with CD included in our study (16%) is high due to how the 
sample was selected are limitations of our study. 
Conclusions
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not negligible and probably has been underestimated for years in many areas, due to the infections 
frequently presenting subclinically. Therefore, serology seems mandatory for the type of patients 
considered here, and the use of eosinophilia as a previous screening method could facilitate the task, 
decreasing the number of analyses to be performed.
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Table 1. Demographic and epidemiological characteristics of studied population and according to S. Stercolaris serology 
Strongyloides stercoralis serology
Total Negative Positive
Categorical N Freq. % N Freq. % Freq. % p
Gender Female 267 195 73.0 263 169 87.6 24 12.4 0.038
Male 72 27.0 54 77.1 16 22.9
Age (years) <18 267 4 1.5 263 4 100.0 0 0.0
18-65 259 97.0 215 84.3 40 15.7 0.261
>65 4 1.5 4 100.0 0 0.0
Country of origin Bolivia 267 187 70.0 263 156 83.4 31 16.6 0.113
Paraguay 4 1.5 4 100.0 0 0.0
EL Salvador 2 0.7 2 100.0 0 0.0
Brazil 1 0.4 1 100.0 0 0.0
Argentina 1 0.4 1 100.0 0 0.0
Uruguay 1 0.4 0 0.0 1 100.0
Honduras 1 0.4 0 0.0 1 100.0
Unknown 70 26.2 59 89.4 7 10.6
Eosinophil count Normal 267 180 67.4 263 177 98.9 2 1.1 <0.001
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S. stercoralis Negative 267 223 83.5
Positive 40 15.0
Inconclusive 4 1.5
Continuous N Mean SD N Mean SD Mean SD p
Age (years) 267 37.17 10.54 263 36.74 10.57 39.35 10.56 0.151
Eosinophil 
(x109/L)
267 0.4157 0.41698 263 0.2936 0.26624 1.0458 0.49419 <0.001
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Table 2. Simple and age-gender-adjusted ratios of association: eosinophilia and S. stercoralis infection
Not Adjusted OR 95% CI Adjusted OR 95% CI p
Constant 0.011 0.003
Eosinophil ≤ 0.5.10 9 /L 73.109 17.005-314.311 75.584 17.344-329.079 <0.001
Gender (Female) 2.086 1.033-4.214 1.623 0.674-3.907 0.280
Age 1.022 0.992-1.053 1.034 0.996-1.074 0.082
OR. = Odds ratio, 95% CI=Confidence Interval 95%





Eosinophil count ≥ 0.5.10 9 /L 38 46














Positive predictive value 45% 34-56
Negative predictive value 99% 96-100
